Iza-Bren/Izalontamab Brengitecan (BL-B01D1) (EGFR/HER3 Bispecific ADC)

2026-05-21 — Bristol Myers Squibb (NYSE: BMY) announced it will present oncology portfolio and pipeline data at the 2026 ASCO Annual Meeting (May 29–June 2, Chicago), with more than 60 disclosures and 19 oral presentations spanning solid tumors and hematologic malignancies.

Key late-breaking and other highlighted presentations include: Phase 3 SUCCESSOR-2 full results for investigational oral CELMoD mezigdomide plus carfilzomib/dexamethasone vs carfilzomib/dexamethasone in relapsed/refractory multiple myeloma; safety and 12‑month efficacy for investigational lymphoma CELMoD golcadomide plus pola‑RCHP in newly diagnosed aggressive B‑cell lymphoma; and efficacy/safety for investigational CELMoD iberdomide in newly diagnosed multiple myeloma.

Additional pipeline updates include Phase 3 data in Mainland China for izalontamab brengitecan (iza‑bren; EGFRxHER3 bispecific ADC) in triple‑negative breast cancer and esophageal squamous cell carcinoma (with BMS co-development outside China), and Phase 2 data for BioNTech-partnered pumitamig (PD‑L1 x VEGF‑A bispecific) plus chemotherapy in first-line NSCLC. The release also notes real-world outcomes analyses for CAR T therapies, including Breyanzi (lisocabtagene maraleucel).